The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

Journal of Cellular Biochemistry

Volumn 113, Issue 3, 2012, Pages 784-791

  Awasthi, Niranjan ^a,b   Yen, Peter L ^a,b   Schwarz, Margaret A ^a   Schwarz, Roderich E ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Combination Therapy; Gemcitabine; Nvp Bez235; Pancreatic Cancer

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CASPASE 3; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DEOXYCYTIDINE; ENZYME INHIBITORS; FEMALE; FIBROBLASTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; MICE; MICE, SCID; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; QUINOLINES; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

ANIMALIA; MAMMALIA; MURINAE;

EID: 84857579424     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23405     Document Type: Article

References (39)

1. Agbunag C, Bar-Sagi D. 2004. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 64:5659-5663. (Pubitemid 39095562)
2. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. 2004. The PI 3-kinase/ Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23:8571-8580. (Pubitemid 39576463)
3. Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE. 2009. Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling. Lab Invest 89:38-46.
4. Bardeesy N, DePinho RA. 2002. Pancreatic cancer biology and genetics. Nat Rev Cancer 2:897-909. (Pubitemid 37328891)
5. Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger E, Figg WD, Grove A, Kohn E, Stern D, Libutti SK. 2000. Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. Microvasc Res 60:70-80. (Pubitemid 30456829)
6. Brennan MF. 2004. Adjuvant therapy following resection for pancreatic adenocarcinoma. Surg Oncol Clin N Am 13:555-566, vii.
7. Cao P, Maira SM, Garcia-Echeverria C, Hedley DW. 2009. Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 100: 1267-1276.
8. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, Tan D, Brattain MG, Javle MM. 2006. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 13:933-939.
9. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. 2005. The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene 24:7482-7492. (Pubitemid 41637988)
10. Duffy JP, Eibl G, Reber HA, Hines OJ. 2003. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2:12.
11. Hayes AJ, Li LY, Lippman ME. 2000. Anti-vascular therapy: A new approach to cancer treatment. West J Med 172:39-42.
12. Herrera VA, Zeindl-Eberhart E, Jung A, Huber RM, Bergner A. 2011. The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines. Anticancer Res 31:849-854.
13. Ito D, Fujimoto K, Mori T, Kami K, Koizumi M, Toyoda E, Kawaguchi Y, Doi R. 2006. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int J Cancer 118: 2337-2343.
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
15. Kalluri R, Zeisberg M. 2006. Fibroblasts in cancer. Nat Rev Cancer 6:392-401.
16. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Boothman DA, Scaglioni PP. 2009. Dual phosphoinositide 3-kinase/ mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 69:7644-7652.
17. MacKenzie MJ. 2004. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5:541-549.
18. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C. 2008. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7:1851-1863.
19. Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, Garcia-Echeverria C, Mercuri M, Picci P, Scotlandi K. 2010. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res 16:530-540.
20. Ng SSW, Tsao MS, Chow S, Hedley DW. 2000. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60:5451-5455.
21. Ng SS, Tsao MS, Nicklee T, Hedley DW. 2001. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Clin Cancer Res 7:3269-3275. (Pubitemid 32963853)
22. Oikawa T, Hitomi J, Kono A, Kaneko E, Yamaguchi K. 1995. Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. Int J Pancreatol 18:15-23.
23. Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN. 1994. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54:1556-1560. (Pubitemid 24106422)
24. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. 2005. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial. Lancet Oncol 6:369-376. (Pubitemid 40753742)
25. Rosewicz S, Wiedenmann B. 1997. Pancreatic carcinoma. Lancet 349: 485-489. (Pubitemid 27077838)
26. Santiskulvong C, Konecny GE, Fekete M, Chen KY, Karam A, Mulholland D, Eng C, Wu H, Song M, Dorigo O. 2011. Dual targeting of phosphoinositide 3- kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin Cancer Res 17:2373-2384.
27. Schneider G, Siveke JT, Eckel F, Schmid RM. 2005. Pancreatic cancer: Basic and clinical aspects. Gastroenterology 128:1606-1625. (Pubitemid 40692555)
28. Schwarz RE, Schwarz MA. 2004. In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. J Surg Res 120:64-72. (Pubitemid 38686531)
29. Schwarz MA, Kandel J, Brett J, Li J, Hayward J, Schwarz RE, Chappey O, Wautier JL, Chabot J, Lo Gerfo P, Stern D. 1999a. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med 190:341-354.
30. Schwarz RE, McCarty TM, Peralta EA, Diamond DJ, Ellenhorn JD. 1999b. An orthotopic in vivo model of human pancreatic cancer. Surgery 126:562-567. (Pubitemid 29421045)
31. Schwarz MA, Zhang F, Gebb S, Starnes V, Warburton D. 2000. Endothelial monocyte activating polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis. Mech Dev 95:123-132. (Pubitemid 30440800)
32. Schwarz MA, Zheng H, Liu J, Corbett S, Schwarz RE. 2005. Endothelialmonocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrin. Exp Cell Res 311: 229-239. (Pubitemid 41636316)
33. Schwarz RE, Konduri S, Awasthi N, Cafasso D, Schwarz MA. 2009. An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer. Surgery 146:241-249.
34. Schwarz RE, Awasthi N, Konduri S, Cafasso D, Schwarz MA. 2010a. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer. Ann Surg Oncol 17:1442-1452.
35. Schwarz RE, Awasthi N, Konduri S, Caldwell L, Cafasso D, Schwarz MA. 2010b. Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biol Ther 9:632-639.
36. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J. 2008. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68:8022-8030.
37. Vivanco I, Sawyers CL. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501. (Pubitemid 37328931)
38. Warshaw AL, Fernandez-del Castillo C. 1992. Pancreatic carcinoma. N Engl J Med 326:455-465.
39. Wilkowski R, Thoma M, Bruns C, Duhmke E, Heinemann V. 2006. Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer. JOP 7:34-40. (Pubitemid 43103797)